

Gary Cook

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6574373/publications.pdf>

Version: 2024-02-01

211
papers

11,966
citations

34105

52
h-index

30087

103
g-index

215
all docs

215
docs citations

215
times ranked

13555
citing authors

#	ARTICLE	IF	CITATIONS
1	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. <i>Radiology</i> , 2020, 295, 328-338.	7.3	1,869
2	Imaging biomarker roadmap for cancer studies. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 169-186.	27.6	792
3	Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. <i>Insights Into Imaging</i> , 2012, 3, 573-589.	3.4	738
4	Introduction to Radiomics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 488-495.	5.0	673
5	Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 133-140.	6.4	395
6	Are Pretreatment ¹⁸ F-FDG PET Tumor Textural Features in Non-Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?. <i>Journal of Nuclear Medicine</i> , 2013, 54, 19-26.	5.0	361
7	Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation. <i>Seminars in Nuclear Medicine</i> , 1996, 26, 308-314.	4.6	358
8	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
9	Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 28-49.	4.6	254
10	Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. <i>Seminars in Nuclear Medicine</i> , 2004, 34, 122-133.	4.6	241
11	Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1363-1378.	6.4	228
12	Positron emission tomography and bone metastases. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 135-142.	4.6	218
13	Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. <i>European Radiology</i> , 2014, 24, 998-1005.	4.5	181
14	Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. <i>Insights Into Imaging</i> , 2015, 6, 489-497.	3.4	149
15	Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of ¹⁸ F-FDG Uptake at PET Association with Treatment Response and Prognosis. <i>Radiology</i> , 2015, 276, 883-893.	7.3	147
16	Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. <i>PLoS ONE</i> , 2015, 10, e0137036.	2.5	139
17	The role of positron emission tomography in the management of bone metastases. <i>Cancer</i> , 2000, 88, 2927-2933.	4.1	137
18	Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. <i>American Journal of Roentgenology</i> , 2016, 207, 534-543.	2.2	121

#	ARTICLE	IF	CITATIONS
19	Challenges and Promises of PET Radiomics. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1083-1089.	0.8	121
20	Early Phase I Study of a ^{99m} Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. Journal of Nuclear Medicine, 2019, 60, 1213-1220.	5.0	111
21	Radiomics in PET: principles and applications. Clinical and Translational Imaging, 2014, 2, 269-276.	2.1	103
22	The incorporation of SPECT functional lung imaging into inverse radiotherapy planning for non-small cell lung cancer. Radiotherapy and Oncology, 2005, 77, 271-277.	0.6	100
23	Patterns, Variants, Artifacts, and Pitfalls in Conventional Radionuclide Bone Imaging and SPECT/CT. Seminars in Nuclear Medicine, 2009, 39, 380-395.	4.6	99
24	¹⁸ F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with ²²³ Ra-chloride (Alpharadin). EJNMMI Research, 2011, 1, 4.	2.5	99
25	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase Deficient Thoracic Cancers. Journal of Clinical Oncology, 2017, 35, 1778-1785.	1.6	96
26	The role of positron emission tomography in skeletal disease. Seminars in Nuclear Medicine, 2001, 31, 50-61.	4.6	94
27	Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using ¹⁸ F-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study. Journal of Nuclear Medicine, 2017, 58, 891-898.	5.0	91
28	Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. Journal of Nuclear Medicine, 2016, 57, 27S-33S.	5.0	84
29	A Prospective Study of Risedronate on Regional Bone Metabolism and Blood Flow at the Lumbar Spine Measured by ¹⁸ F-Fluoride Positron Emission Tomography. Journal of Bone and Mineral Research, 2003, 18, 2215-2222.	2.8	82
30	Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. Ecological Management and Restoration, 2015, 28, 172-179.	0.4	77
31	A potential to reduce pulmonary toxicity: The use of perfusion SPECT with IMRT for functional lung avoidance in radiotherapy of non-small cell lung cancer. Radiotherapy and Oncology, 2007, 83, 156-162.	0.6	76
32	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	2.2	70
33	The role of nuclear medicine in monitoring treatment in skeletal malignancy. Seminars in Nuclear Medicine, 2001, 31, 206-211.	4.6	69
34	Dissociation Between Global Markers of Bone Formation and Direct Measurement of Spinal Bone Formation in Osteoporosis. Journal of Bone and Mineral Research, 2004, 19, 1797-1804.	2.8	67
35	Miscellaneous Cancers (Lung, Thyroid, Renal Cancer, Myeloma, and Neuroendocrine Tumors): Role of SPECT and PET in Imaging Bone Metastases. Seminars in Nuclear Medicine, 2009, 39, 416-430.	4.6	66
36	The precision of textural analysis in ¹⁸ F-FDG-PET scans of oesophageal cancer. European Radiology, 2015, 25, 2805-2812.	4.5	66

#	ARTICLE	IF	CITATIONS
37	Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. <i>Radiology</i> , 2017, 284, 552-561.	7.3	66
38	Non-invasive assessment of skeletal kinetics using fluorine-18 fluoride positron emission tomography: evaluation of image and population-derived arterial input functions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1424-1429.	6.4	63
39	Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. <i>Radiotherapy and Oncology</i> , 2004, 73, 277-283.	0.6	63
40	Long-Term Precision of ¹⁸ F-Fluoride PET Skeletal Kinetic Studies in the Assessment of Bone Metabolism. <i>Journal of Nuclear Medicine</i> , 2008, 49, 700-707.	5.0	62
41	Differences in Skeletal Kinetics Between Vertebral and Humeral Bone Measured by 18F-Fluoride Positron Emission Tomography in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2010, 15, 763-769.	2.8	61
42	Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2971-2980.	1.6	61
43	18F-Fluorodeoxyglucose Positron Emission Tomography for the Evaluation of Neoadjuvant Therapy Response in Esophageal Cancer. <i>Annals of Surgery</i> , 2009, 250, 247-254.	4.2	59
44	The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 276-282.	6.4	59
45	Radiomics in esophageal and gastric cancer. <i>Abdominal Radiology</i> , 2019, 44, 2048-2058.	2.1	59
46	Discovery of pre-therapy 2-deoxy-2-18F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 455-466.	6.4	59
47	Skeletal metastases from breast cancer: Imaging with nuclear medicine. <i>Seminars in Nuclear Medicine</i> , 1999, 29, 69-79.	4.6	58
48	Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. <i>Clinical and Translational Imaging</i> , 2016, 4, 439-447.	2.1	56
49	The CT flare response of metastatic bone disease in prostate cancer. <i>Acta Radiologica</i> , 2011, 52, 557-561.	1.1	55
50	¹⁸ F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1666-1671.	5.0	55
51	Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 1-4.	0.6	54
52	The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 7-13.	6.4	54
53	Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?. <i>Clinical Radiology</i> , 2015, 70, 1060-1082.	1.1	54
54	Molecular imaging of hypoxia in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 956-976.	6.4	50

#	ARTICLE	IF	CITATIONS
55	The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer. <i>EJNMMI Research</i> , 2017, 7, 60.	2.5	50
56	Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 316-324.	0.8	50
57	The role of new PET tracers for lung cancer. <i>Lung Cancer</i> , 2016, 94, 7-14.	2.0	47
58	New Horizons in Oncologic Imaging. <i>New England Journal of Medicine</i> , 2003, 348, 2487-2488.	27.0	45
59	Differences in regional bone perfusion and turnover between lumbar spine and distal humerus: 18F-fluoride PET study of treatment-naïve and treated postmenopausal women. <i>Bone</i> , 2009, 45, 942-948.	2.9	44
60	Effective avoidance of a functional spect-perfused lung using intensity modulated radiotherapy (IMRT) for non-small cell lung cancer (NSCLC): An update of a planning study. <i>Radiotherapy and Oncology</i> , 2009, 91, 349-352.	0.6	43
61	Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18 F-fluorodeoxyglucose positron emission tomography/CT (18 F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 66-72.	4.4	43
62	Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer. <i>Radiotherapy and Oncology</i> , 2010, 97, 101-107.	0.6	42
63	The role of 18F-FDG PET/CT in the management of testicular cancers. <i>Nuclear Medicine Communications</i> , 2015, 36, 702-708.	1.1	40
64	Review article: PET and PET/CT imaging of skeletal metastases. <i>Cancer Imaging</i> , 2010, 10, 153-160.	2.8	39
65	Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2013, 106, 112-117.	0.6	39
66	PET/MRI in Oncological Imaging: State of the Art. <i>Diagnostics</i> , 2015, 5, 333-357.	2.6	37
67	Molecular Imaging of Bone Metastases and Their Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 799-806.	5.0	37
68	Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. <i>Radiotherapy and Oncology</i> , 2020, 144, 72-78.	0.6	35
69	[18 F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. <i>European Urology</i> , 2017, 71, 926-933.	1.9	34
70	Is FDGâ€PET suitable for evaluating neoadjuvant therapy in nonâ€small cell lung cancer? Evidence with systematic review of the literature. <i>Journal of Surgical Oncology</i> , 2010, 101, 486-494.	1.7	33
71	Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features. <i>British Journal of Radiology</i> , 2019, 92, 20190159.	2.2	32
72	Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 821-830.	6.4	31

#	ARTICLE	IF	CITATIONS
73	The Relationship Between Regional Bone Turnover Measured Using 18F-fluoride Positron Emission Tomography and Changes in BMD Is Equivalent to That Seen for Biochemical Markers of Bone Turnover. <i>Journal of Clinical Densitometry</i> , 2007, 10, 46-54.	1.2	30
74	Imaging Breast Cancer Bone Metastases: Current Status and Future Directions. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 317-323.	4.6	30
75	Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers. <i>Clinical Nuclear Medicine</i> , 2016, 41, e44-e50.	1.3	30
76	An evaluation of Technegas as a ventilation agent compared with krypton-81 m in the scintigraphic diagnosis of pulmonary embolism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1992, 19, 770-4.	2.1	29
77	18F-FDG PET/CT in HIV-related central nervous system pathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1420-1427.	6.4	29
78	The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 674-686.	6.4	29
79	Evaluation of the role of ¹⁸ F-FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer. <i>Acta Oncologica</i> , 2008, 47, 1229-1236.	1.8	28
80	Staging FDG PET-CT changes management in patients with gastric adenocarcinoma who are eligible for radical treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 759-767.	6.4	28
81	Adaptive statistical iterative reconstruction (ASIR) affects CT radiomics quantification in primary colorectal cancer. <i>European Radiology</i> , 2019, 29, 5227-5235.	4.5	27
82	Miscellaneous Indications in Bone Scintigraphy: Metabolic Bone Diseases and Malignant Bone Tumors. <i>Seminars in Nuclear Medicine</i> , 2010, 40, 52-61.	4.6	23
83	Molecular Imaging in the Management of Adrenocortical Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e368-e382.	1.3	23
84	Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of ¹⁸ F-Fluoride Metabolic Flux Than with Measurement of ¹⁸ F-Fluoride PET/CT SUV?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 322-327.	5.0	23
85	Multi-technique imaging of bone metastases: spotlight on PET-CT. <i>Clinical Radiology</i> , 2016, 71, 620-631.	1.1	22
86	Can 18F-FDG PET/CT Reliably Assess Response to Primary Treatment of Head and Neck Cancer?. <i>Clinical Nuclear Medicine</i> , 2013, 38, 263-265.	1.3	21
87	Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1845-1852.	6.4	21
88	18F-FDG PET Rarely Provides Additional Information to 11C-Methionine PET Imaging in Hyperparathyroidism. <i>Clinical Nuclear Medicine</i> , 2014, 39, 237-242.	1.3	20
89	Comparative assessment of small intestinal and colonic permeability in HIV-infected homosexual men. <i>Aids</i> , 1995, 9, 1009-1016.	2.2	19
90	Dual-modality imaging. <i>European Radiology</i> , 2001, 11, 1857-1858.	4.5	19

#	ARTICLE	IF	CITATIONS
91	Texture analysis of 125I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. <i>British Journal of Cancer</i> , 2015, 112, 1882-1887.	6.4	19
92	Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI. <i>European Journal of Radiology</i> , 2019, 115, 46-52.	2.6	19
93	Radiomic analysis for response assessment in advanced head and neck cancers, a distant dream or an inevitable reality? A systematic review of the current level of evidence. <i>British Journal of Radiology</i> , 2020, 93, 20190496.	2.2	19
94	Renovascular Disease. <i>Clinical Radiology</i> , 2000, 55, 1-12.	1.1	18
95	Validation of image-derived arterial input functions at the femoral artery using 18F-fluoride positron emission tomography. <i>Nuclear Medicine Communications</i> , 2011, 32, 808-817.	1.1	18
96	Validation of new image-derived arterial input functions at the aorta using 18F-fluoride positron emission tomography. <i>Nuclear Medicine Communications</i> , 2011, 32, 486-495.	1.1	18
97	Comparison of six quantitative methods for the measurement of bone turnover at the hip and lumbar spine using 18F-fluoride PET-CT. <i>Nuclear Medicine Communications</i> , 2012, 33, 597-606.	1.1	18
98	Sentinel lymph node biopsy in breast cancer. <i>Nuclear Medicine Communications</i> , 2016, 37, 570-576.	1.1	18
99	Functional and Hybrid Imaging of Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 961-972.	2.8	18
100	Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. <i>European Radiology</i> , 2012, 22, 1465-1478.	4.5	17
101	Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. <i>BMC Cancer</i> , 2017, 17, 494.	2.6	17
102	Thyroid Paraganglioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 416-423.	1.3	17
103	Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1478-1484.	6.4	17
104	Functional imaging techniques in hepatocellular carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1070-1079.	6.4	16
105	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. <i>Clinical Nuclear Medicine</i> , 2015, 40, e259-e264.	1.3	16
106	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. <i>Oncologist</i> , 2016, 21, 1502-1508.	3.7	16
107	The effect of post-injection 18F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1. <i>EJNMMI Research</i> , 2017, 7, 35.	2.5	16
108	MRI or Bone Scan or Both for Staging of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2007, 25, 5837-5838.	1.6	15

#	ARTICLE	IF	CITATIONS
109	A Role for Tumor Volume Assessment in Resectable Esophageal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3063-3070.	1.5	15
110	What can artificial intelligence teach us about the molecular mechanisms underlying disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2715-2721.	6.4	15
111	MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 119-126.	0.6	15
112	Lateral collateral ligament tear of the knee: appearances on bone scintigraphy with single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 720-722.	2.1	14
113	Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomographyâ€“computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication. <i>Nuclear Medicine Communications</i> , 2013, 34, 1075-1083.	1.1	14
114	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18Fâ€“Fluorodeoxyglucose (18Fâ€“FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. <i>BMC Cancer</i> , 2017, 17, 392.	2.6	14
115	Systematic review of research design and reporting of imaging studies applying convolutional neural networks for radiological cancer diagnosis. <i>European Radiology</i> , 2021, 31, 7969-7983.	4.5	14
116	¹⁸ F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. <i>Radiology</i> , 2022, 304, 246-264.	7.3	14
117	Diagnostic 131I whole body scanning after thyroidectomy and ablation for differentiated thyroid cancer. <i>European Journal of Endocrinology</i> , 2004, 150, 649-653.	3.7	13
118	Positron emission tomography in oncology. <i>British Medical Bulletin</i> , 2006, 79-80, 171-186.	6.9	13
119	Ensuring the right PET scan for the right patient. <i>Lung Cancer</i> , 2008, 59, 48-56.	2.0	13
120	Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 1197-1206.	1.1	13
121	Multitracer Guided PET Image Reconstruction. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2018, 2, 499-509.	3.7	13
122	Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2558-2565.	6.4	13
123	Follicular Thyroid Carcinoma Metastasis to the Esophagus Detected by 18FDG PET/CT. <i>Thyroid</i> , 2008, 18, 267-271.	4.5	12
124	Imaging Tumor Response and Tumoral Heterogeneity in Nonâ€“Small Cell Lung Cancer Treated With Antiangiogenic Therapy. <i>Journal of Thoracic Imaging</i> , 2015, 30, 300-307.	1.5	12
125	PET Imaging of Skeletal Metastases and Its Role in Personalizing Further Management. <i>PET Clinics</i> , 2016, 11, 305-318.	3.0	12
126	A Role for FDG PET Radiomics in Personalized Medicine?. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 532-540.	4.6	12

#	ARTICLE	IF	CITATIONS
127	FDG PET-CT: Need for vigilance in patients treated with bleomycin. Indian Journal of Nuclear Medicine, 2017, 32, 122.	0.3	12
128	Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET?. Molecular Imaging and Biology, 2019, 21, 781-789.	2.6	11
129	Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma. Clinical Cancer Research, 2021, 27, 6457-6466.	7.0	11
130	Preparation and Use of 131I Magic Gel as a Dosimeter for Targeted Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 427-436.	1.0	10
131	Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nuclear Medicine Communications, 2015, 36, 815-818.	1.1	10
132	Multimodal Partial-Volume Correction: Application to ¹⁸ F-Fluoride PET/CT Bone Metastases Studies. Journal of Nuclear Medicine, 2015, 56, 1408-1414.	5.0	10
133	Challenges in imaging assessment following liver stereotactic body radiotherapy: pitfalls to avoid in clinical practice. Chinese Clinical Oncology, 2017, 6, S11-S11.	1.2	10
134	Positron-emission Tomography Used to Diagnose Tuberculosis in a Renal Transplant Patient. American Journal of Transplantation, 2002, 2, 105-107.	4.7	9
135	The isotope bone scan: we can do better. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1139-1140.	6.4	9
136	Sentinel Lymph Node Biopsy in Pelvic Tumors. Clinical Nuclear Medicine, 2016, 41, e288-e293.	1.3	9
137	Imaging α 2 β 3 integrin expression in skeletal metastases with 99mTc-maraciclalide single-photon emission computed tomography: detection and therapy response assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 898-903.	6.4	9
138	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer. BMC Medical Imaging, 2019, 19, 90.	2.7	9
139	Imaging with radiolabelled bisphosphonates. Bone, 2020, 137, 115372.	2.9	9
140	Standardisation of conventional and advanced iterative reconstruction methods for Gallium-68 multi-centre PET-CT trials. EJNMMI Physics, 2021, 8, 52.	2.7	8
141	[18F] Sodium Fluoride PET Kinetic Parameters in Bone Imaging. Tomography, 2021, 7, 843-854.	1.8	8
142	Successful repeat transcatheter ablation of a mediastinal parathyroid adenoma 6 years after alcohol embolization. CardioVascular and Interventional Radiology, 1997, 20, 314-316.	2.0	7
143	Is there a role for PET/CT in the evaluation of primary and secondary hyperparathyroidism?. Nuclear Medicine Communications, 2016, 37, 1-2.	1.1	7
144	Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. Nuclear Medicine Communications, 2019, 40, 611-617.	1.1	7

#	ARTICLE	IF	CITATIONS
145	A Multi-Channel Uncertainty-Aware Multi-Resolution Network for MR to CT Synthesis. Applied Sciences (Switzerland), 2021, 11, 1667.	2.5	7
146	Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI. European Journal of Hybrid Imaging, 2021, 5, 23.	1.5	7
147	Back pain: Can we make a contribution?. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 363-367.	2.1	6
148	Skeletal metastases: what is the future role for nuclear medicine?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1803-1806.	6.4	6
149	Combined 18F-Fluoride and 18F-FDG PET/CT Scanning for Evaluation of Malignancy: Results of an International Multicenter Trial. Journal of Nuclear Medicine, 2013, 54, 173-175.	5.0	6
150	UK guidelines on 18F-fluciclovine PET/CT in prostate cancer imaging. Nuclear Medicine Communications, 2019, 40, 662-674.	1.1	6
151	Clinical Applications of PET/CT in Oncology. , 2017, , 429-450.		6
152	Positron emission tomography computed tomography in oncology. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 631-637.	0.5	5
153	Positron Emission Tomography/Magnetic Resonance Imaging of Gastrointestinal Cancers. Seminars in Ultrasound, CT and MRI, 2016, 37, 352-357.	1.5	4
154	Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. Biomarkers in Cancer, 2019, 11, 1179299X1985151.	3.6	4
155	Correlations between DWâ€MRI and 18 Fâ€FDG PET / CT parameters in head and neck squamous cell carcinoma following definitive chemoâ€radiotherapy. Cancer Reports, 2021, 4, e1360.	1.4	4
156	Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chinese Clinical Oncology, 2016, 5, 24-24.	1.2	4
157	Reply: Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with ¹⁸ F-Fluoride. Journal of Nuclear Medicine, 2019, 60, 569.1-569.	5.0	4
158	Radiomic assessment of oesophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT. Insights Into Imaging, 2022, 13, .	3.4	4
159	Metastatic Thyroid Carcinoma Causing Superior Vena Caval Obstruction Diagnosed on I-131 Scan. Clinical Nuclear Medicine, 2005, 30, 548-549.	1.3	3
160	Neuron-specific enolase expression in multiple myeloma. Lancet Oncology, The, 2006, 7, 960.	10.7	3
161	What is the role of radionuclide sentinel lymph node biopsy and dissection in papillary thyroid cancer?. Nuclear Medicine Communications, 2015, 36, 969-970.	1.1	3
162	New horizons in multimodality molecular imaging and novel radiotracers. Clinical Medicine, 2017, 17, 444-448.	1.9	3

#	ARTICLE	IF	CITATIONS
163	PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer. <i>BJU International</i> , 2019, 124, 357-358.	2.5	3
164	Optimisation of CT protocols in PET-CT across different scanner models using different automatic exposure control methods and iterative reconstruction algorithms. <i>EJNMMI Physics</i> , 2021, 8, 58.	2.7	3
165	Imaging of Bone Metastases in Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 531-541.	4.6	3
166	Artefacts and Normal Variants in Whole-Body PET and PET/CT Imaging. , 2005, , 281-293.		2
167	Unusual presentation of metastatic adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 116.	1.9	2
168	Case report: PET/CT, a cautionary tale. <i>BMC Cancer</i> , 2007, 7, 147.	2.6	2
169	Imaging Assessment of Lung Tumor Angiogenesis: Insights and Innovations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 112-128.	2.1	2
170	Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy. <i>Translational Oncology</i> , 2017, 10, 459-467.	3.7	2
171	Guided Image Reconstruction for Multi-Tracer PET. , 2017, , .		2
172	Temporospatial heterogeneity of acquired resistance mechanisms in EGFR-mutant lung adenocarcinoma: A case of concurrent EGFR mutation and small cell transformation. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100106.	0.1	2
173	Physiologic and Molecular Basis of PET in Cancer Imaging. , 2017, , 399-427.		2
174	PET Imaging of the Skeleton. , 2006, , 317-335.		2
175	Sparse Regression in Cancer Genomics: Comparing Variable Selection and Predictions in Real World Data. <i>Cancer Informatics</i> , 2021, 20, 117693512110562.	1.9	2
176	Radiomic Analysis of Tumour Heterogeneity Using MRI in Head and Neck Cancer Following Chemoradiotherapy: A Feasibility Study. <i>Frontiers in Oncology</i> , 2022, 12, 784693.	2.8	2
177	Issues undermining provision of diagnostic imaging in the UK. <i>Lancet Oncology</i> , The, 2004, 5, 467-468.	10.7	1
178	¹⁸ F-Fluoride PET and PET/CT Imaging of Skeletal Metastases. <i>PET Clinics</i> , 2010, 5, 275-280.	3.0	1
179	Influence of three reconstruction algorithms on the estimation of the standardize uptake value in ¹⁸ F-fluoride PET. , 2013, , .		1
180	Fluorodeoxyglucose positron emission tomography (¹⁸ F-FDG PET)/computed tomography (¹⁸ F-FDG PET/CT) in bladder cancer. <i>BJU International</i> , 2013, 112, 709-709.	2.5	1

#	ARTICLE	IF	CITATIONS
181	Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 16-17.	6.4	1
182	The Role of PET-CT Imaging in Prostate Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 373-391.	1.5	1
183	Artifacts and Normal Variants in Whole-Body PET and PET/CT Imaging. , 2006, , 63-77.		1
184	Elevated CEA level in the asymptomatic patient with normal conventional imaging: How useful is PET-CT for the detection of colorectal cancer recurrence?. <i>Journal of Clinical Oncology</i> , 2012, 30, 400-400.	1.6	1
185	Measuring validity of response assessment in bone predominant metastatic breast cancer based on clinico-radiological evaluation: An Inter-observer study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13055-e13055.	1.6	1
186	Nuclear Medicine Imaging Techniques of the Musculoskeletal System. , 2020, , 381-430.		1
187	Preclinical development and characterisation of Tc-NM-01 for SPECT/CT imaging of human PD-L1. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 154-166.	1.0	1
188	What's new in â€¦ Positron emission tomography. <i>Medicine</i> , 2004, 32, 1-4.	0.4	0
189	Clinical PET Imaging. , 2005, , 347-364.		0
190	Positron Emmision Tomography in Lung Cancer. , 0, , 84-98.		0
191	Radioisotope and PET Imaging of Bone Metastases. , 2006, , 77-90.		0
192	Perioperative use of radioisotopes. <i>Surgery</i> , 2008, 26, 261-268.	0.3	0
193	Corrigendum to â€œRandomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancerâ€•[<i>Radiother Oncol</i> 97 (2010) 101â€“107]. <i>Radiotherapy and Oncology</i> , 2011, 98, 285.	0.6	0
194	Bone metastases in prostate cancer: which scan?. <i>BJU International</i> , 2014, 114, 792-793.	2.5	0
195	Challenges for imaging and therapy of musculoskeletal tumours. <i>Clinical and Translational Imaging</i> , 2015, 3, 79-81.	2.1	0
196	An Incidental Renal Oncocytoma: 18F-Choline PET/MRI. <i>Diagnostics</i> , 2016, 6, 14.	2.6	0
197	One Coin, No Need to Flip: Shared PET Targets in Cancer and Coronary Artery Disease. <i>American Journal of Roentgenology</i> , 2017, 208, 434-445.	2.2	0
198	Imaging of Tumour Heterogeneity: Functional MR Techniques in Oncology. , 2018, , 131-150.		0

#	ARTICLE	IF	CITATIONS
199	18F-FDG PET-CT and 18F-NaF in Treatment Response Evaluation: Bone Metastases and Bone Tumours. , 2021, , 403-417.		0
200	An overview of nuclear medicine research in the UK and the landscape for clinical adoption. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 1301-1312.	1.1	0
201	PET-CT of Esophageal Cancer. , 2011, , 181-191.		0
202	Lung, Thyroid, Renal Cancer, Myeloma and Neuroendocrine Cancers: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 691-715.		0
203	Bone Scintigraphy in Metabolic Bone Disease. , 2012, , 435-444.		0
204	Primary Bone and Soft Tissue Tumours: Role of 18FDG PET. , 2012, , 777-786.		0
205	Conventional Nuclear Medicine and Hybrid Imaging in Monitoring the Treatment of Skeletal Malignancy. , 2012, , 717-734.		0
206	An Unusual Pathologic Fracture in Metastatic Prostate Cancer. Clinical Nuclear Medicine, 1998, 23, 554.	1.3	0
207	Assessment of tumoral heterogeneity in NSCLC treated with bevacizumab: A prospective study.. Journal of Clinical Oncology, 2014, 32, e19124-e19124.	1.6	0
208	Multiparametric MRI assessment during cisplatin and trastuzumab therapy in esophageal adenocarcinoma xenografts.. Journal of Clinical Oncology, 2015, 33, e15108-e15108.	1.6	0
209	Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer.. Journal of Clinical Oncology, 2015, 33, TPS2612-TPS2612.	1.6	0
210	Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft.. Journal of Clinical Oncology, 2016, 34, 42-42.	1.6	0
211	The role of new PET tracers for lung cancer. Minerva Pneumologica, 2019, 58, .	1.6	0